Atara Biotherapeutics announces $150 million stock offering
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
CFO of Atara Biotherapeutics announces retirement
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara Biotherapeutics gets OK to study multiple sclerosis treatment
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara Biotherapeutics stock falls on details of secondary stock offering
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Conejo Spectrum lands Atara Biotherapeutics
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara Biotherapeutics angles for $92M, but jobs are scarce
Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.
Round 2: Atara raises $13.5M as T.O. biotech boom takes hold
Thousand Oaks-based Atara Biotherapeutics has brought on more investors to its second financing round, bringing the total raised to $52 million.
